Epigenetic Alterations in Pancreatic Cancer
Journal Title: Pancreas – Open Journal - Year 2016, Vol 1, Issue 2
Abstract
Pancreatic cancer is the fourth leading cause of cancer death and is predicted to be the second leading cause in a decade in the US. Despite more than 50 years of research and therapeutic development, pancreatic cancer still has a median survival rate of 6 months and a 5-year overall survival around 5%. Therefore, there is an urgent need to better understand the mechanism of pancreatic cancer development, as well as to discover new biomarkers for early diagnosis, prognosis, and therapeutic targets.
Authors and Affiliations
Jiaqi Shi
Keywords
Related Articles
- EP ID EP556665
- DOI 10.17140/POJ-1-e002
- Views 198
- Downloads 0
β-cell Heterogeneity: The Key to β-cell Replacement Therapy
Cellular heterogeneity is crucial for organisms to adapt to their environmental changes. It provides the morphological, functional and molecular diversity that allows tissues and organs to respond to stressors and mainta...
The Enigma of Type 3c Diabetes in Chronic Pancreatitis
Pancreatogenic or Type 3c diabetes (T3cDM) is relatively a new entry in the complex world of diabetes study. While the general population and physicians are well aware of type 1 and type 2 diabetes mellitus, as evidenced...
Eus-Pancreaticogastrostomy in a Patient with Subtotal Gastrectomy and Roux-En-Y Reconstruction
Chronic Pancreatitis (CP) is often associated with pain due to pancreatic duct obstruction. In these patients, surgical drainage was more effective than endoscopic treatment, achieving a faster, effective, and sustained...
Desmoplastic Reaction in Pancreatic Ductal Adenocarcinoma
Despite significant effort and research funds, Pancreatic Ductal Adenocarcinoma (PDAC) remains one of the deadliest diseases. This cancer is characterized by a distinct desmoplastic reaction that constitutes 80% of the t...
Epigenetic Alterations in Pancreatic Cancer
Pancreatic cancer is the fourth leading cause of cancer death and is predicted to be the second leading cause in a decade in the US. Despite more than 50 years of research and therapeutic development, pancreatic cancer s...